Allogenic stem cell in diabetic wound

Evaluation of Safety and Effectiveness of Expanded Allogenic Mesenchymal Stem Cells for the Treatment of Neuropatic Diabetic Foot Ulcer (Phase I/II Clinical Trail)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170612034485N2

Enrollment

Registered

2018-02-11

Start date

2019-03-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic diabetic foot Ulcer. Type 2 diabetes mellitus with foot ulcer

Interventions

Intervention group: the volunteers who will receive allogenic mesenchymal stem cells in one session..

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Chronic neuropathic diabetic foot ulcer (more than 6 weeks) with wound classification Wagner II full informed consent for recruitment in the study Suitable tissue perfusion (ABI>0.8) and normal flow of main arteries in lower extremities

Exclusion criteria

Exclusion criteria: Suspected osteomyelitis Using corticosteroid or immuno-suppressor drug Chronic renal failure of Hemodialysis Charco Joint

Design outcomes

Primary

Measure	Time frame
Local and systemic side-effects. Timepoint: Every month up to month 6th. Method of measurement: Clinical examination.;Complete wound healing during study (at least 6 months). Timepoint: Every month up to month 6th. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Esmaeeli Djavid

Iranian academic center for education culture and research

djavid@ut.ac.ir+98 21 6698 9110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026